INTC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intel Corp. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Intel Corp. · Technology
$127.39
-8.4% upside to fair value
Low Conviction
Grade D
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
PFE |
| Current Price |
$127.39 |
$27.64 |
| Fair Value Estimate |
$116.75 |
$30.94 |
| Upside to Fair Value |
-8.4%
|
+12.0%
|
| Market Cap |
$642.6B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
185.2x
|
17.4x
|
| Price / Sales |
11.3x
|
2.5x
|
| Price / FCF |
229.7x
|
14.3x
|
| Revenue Growth YoY |
+25.4%
|
+2.6%
|
| Gross Margin |
38.9%
|
71.3%
|
| Operating Margin |
0.1%
|
25.1%
|
| Return on Equity |
-10.8%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
0.44%
|
6.97%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Intel designs and manufactures CPUs, GPUs, networking silicon, and edge and data-center products across its Client Computing, Data Center and AI, and Intel Foundry segments, employing roughly 85,100 people under CEO Lip-Bu Tan. The business quality is currently low: TTM gross margin is 38.9%, TTM operating margin is 0.1%, TTM net margin is -19.8%, and ROE is -10.8%, so the company is not earning …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
INTC |
PFE |
| Zone Low |
$87.56 |
$23.21 |
| Zone High |
$99.24 |
$26.30 |
| In Buy Zone? |
No
|
No
|